Business
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA. Abstract #1351: Identifying IL-27 dependent biomarkers in lymphocytes, NK cells, and myeloid cells in peripheral blood and the tumor microenvironmentDate and Time: Friday, November 3, 9 a.m.–7 p.m. Pacific Daylight Time (PDT)Location: Exhibit Halls A and B1 – San Diego Convention Center Abstract #468: Characteristics of toripalimab: a next generation anti-PD-1 antibody with potent T cell activation and enhanced clinical efficacy irrespective of PD-L-1 statusDate and Time: Saturday, November 4, 9 a.m.–8:30 p.m. PDTLocation: Exhibit Halls A and B1 – San Diego Convention Center Abstract #1354: Anti-CCR8 antibody SRF114 depletes tumor-infiltrating regulatory T cells in dissociated tumors from patients with head and neck squamous cell carcinomaDate and Time: Saturday, November 4, 9 a.m.–8:30 p.m. PDTLocation: Exhibit Halls A and B1 – San Diego Convention Center About Coherus’ Immuno-oncology PipelineCoherus is developing an innovative immuno-oncology pipeline that will be synergistic with its proven commercial capabilities in oncology. Through an in-licensing agreement with Shanghai Junshi Biosciences Ltd., Coherus is developing toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of nasopharyngeal carcinoma (NPC) is under review by the FDA. Toripalimab is approved in China for the treatment of melanoma, urothelial cancer, esophageal squamous cell carcinoma, NPC and non-small cell lung cancer. Through its acquisition of Surface Oncology, Inc. earlier this year, Coherus’ immuno-oncology pipeline now includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. Casdozokitug (formerly SRF388) is a novel, first-in-class anti-IL-27 antibody currently being evaluated in Phase 2 clinical trials in lung and liver cancer. CHS-114 (formerly SRF114) is a highly selective, competitively positioned, ADCC-enh...